Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00551174 · ClinicalTrials.gov registry record · Phase 4
A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment
A Phase 4 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 4
- Development phase
- 781
- Enrollment target
NCT00551174 is a Phase 4 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 781 participants.
The verdict
NCT00551174, a Phase 4 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 781 participants
- Enrollment target
Study Summary
This 2-arm study was designed to assess the long-term safety and tolerability of intravenous (IV) treatment with 2 mg or 3 mg Bonviva in women with post-menopausal osteoporosis who had previously completed Bonviva study BM16550 (DIVA study; NCT00048074). Patients received Bonviva either 2 mg IV every 2 months, or 3 mg IV every 3 months. Patients also received daily supplementation with vitamin D and calcium. The anticipated time on study treatment was 2+ years, and the target sample size was 500+ individuals.
Interventions
- DRUG ibandronate [Bonviva/Boniva]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 781 participants |
| Start Date | 2004-10 |
| Est. Completion | 2008-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00551174
The ClinicalTrials.gov registry entry for NCT00551174 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 781 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ibandronate [Bonviva/Boniva] is the first listed.
NCT00551174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00551174 about?
NCT00551174 is a clinical study titled "A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment". This 2-arm study was designed to assess the long-term safety and tolerability of intravenous (IV) treatment with 2 mg or 3 mg Bonviva in women with post-menopausal osteoporosis who had previously completed Bonviva study BM16550 (DIVA study; NCT00048074). Patients received Bonviva either 2 mg IV ever...
What is the current status of trial NCT00551174?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 781 participants. The study started on 2004-10. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00551174?
The interventions under investigation include: ibandronate [Bonviva/Boniva] (DRUG).
Who is sponsoring clinical trial NCT00551174?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.